BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 14, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

IDX184: Phase IIb start

Idenix said FDA converted its clinical hold on IDX184 to a partial hold after it submitted data from a Phase I drug-drug interaction study of the compound and fellow HCV candidate IDX320, as well as preclinical studies...

Read the full 165 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >